ClinicalTrials.gg
Not yet recruitingNCT07864493VOICE-NASUpdated Oct 8, 2026

Recorded Parent/Caregiver Voice for Infants With Neonatal Opioid Withdrawal Syndrome

An interventional study of Recorded Parent/Caregiver Voice Playback in Neonatal Opioid Withdrawal Syndrome, Prenatal Opioid Exposure and Opioid Withdrawal, sponsored by University of Manitoba. Not yet recruiting at 2 sites in Canada. Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University of Manitoba · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
0 Days to 28 Days
Sex
All
01

Study summary

Neonatal opioid withdrawal syndrome (NOWS) can affect a newborn infant's ability to eat, sleep, and be consoled after exposure to opioids before birth. Standard care at the participating neonatal units uses the Eat, Sleep, Console (ESC) approach, which emphasizes supportive care and involvement of parents and caregivers.

VOICE-NAS is a two-centre feasibility study evaluating whether a recorded parent/caregiver voice can be safely and practically added to usual ESC-based care for infants with NOWS. Approximately 15 to 20 infants will be enrolled at HSC Women's Hospital and St. Boniface Hospital in Winnipeg, Manitoba.

A parent or caregiver will make a short voice recording in their preferred or native language. The recording may include natural talking, reading, singing, storytelling, or comforting words. The recording will be played for the infant during clinically appropriate feeding and settling periods, usually during the latter part of a feed and/or after feeding while the infant is trying to settle or sleep. Playback will generally last about 20 minutes and will be delivered at a controlled sound level.

The main purpose of the study is to determine whether the intervention can be delivered consistently and safely within routine NICU care. The study will measure whether usable voice recordings can be obtained, how often planned playback sessions are successfully delivered, reasons sessions are missed or stopped, caregiver acceptability, staff workflow issues, and any signs of intolerance.

Clinical information such as ESC assessments, feeding support, medication treatment for NOWS, and hospital length of stay will also be described. The study is not designed to determine whether recorded voice therapy is effective. Results will be used to help design a future larger clinical trial.

Read the detailed description

VOICE-NAS is a prospective, two-site, single-arm feasibility study evaluating recorded parent/caregiver voice playback as a non-pharmacologic adjunct to standard Eat, Sleep, Console (ESC)-based care for infants with neonatal opioid withdrawal syndrome (NOWS).

Approximately 15-20 infants will be enrolled from the neonatal intensive care units at HSC Women's Hospital and St. Boniface Hospital in Winnipeg, Manitoba. Eligible infants will have prenatal opioid exposure and clinical NOWS requiring ongoing NICU management under an ESC-based approach. Opioid-associated polysubstance exposure will not exclude participation if the infant otherwise meets eligibility criteria.

Following written informed consent from the parent/legal guardian, a participating parent/caregiver will provide a recorded voice sample. Caregivers will be encouraged to speak naturally in their preferred or native language; English or French is not required. Recording content may include natural speech, reading, singing, storytelling, or comforting words. The research team is not required to translate the recording content.

Recorded voice playback will be integrated into clinically appropriate feeding and settling periods. Playback may begin during the latter part of feeding and/or immediately after feeding while the infant is settling or attempting to sleep. Direct live parent/caregiver interaction, including feeding, holding, skin-to-skin contact, talking, and consoling, will always take priority over recorded playback.

The initial standardized audio-delivery pathway will use the Dräger Babyleo TN500 developmental-care audio pathway when clinically and operationally available. Playback will be targeted at approximately 45-50 dB(A) at the infant position and will not exceed the protocol-defined maximum of 55 dB(A). Planned playback sessions will generally last approximately 20 minutes unless stopped earlier.

Playback will be withheld, paused, or discontinued if the infant develops signs of distress or clinical instability; if a clinical procedure, assessment, feeding need, or other care activity takes priority; if environmental conditions are unsuitable; if the parent/caregiver requests that playback stop; if the treating clinical team considers continued playback inappropriate; or if the protocol-defined sound parameters cannot be maintained.

The study does not alter or delay standard NOWS management. Decisions regarding ESC care, feeding support, pharmacologic treatment, monitoring, transfer, or discharge will remain under the responsibility of the treating clinical team.

The primary focus is feasibility. Key feasibility outcomes will include successful acquisition of a usable parent/caregiver voice recording and the proportion of prescribed playback sessions successfully delivered. Additional measures will include recruitment and consent, time to obtain a usable recording, missed or interrupted sessions and their reasons, protocol deviations, device or workflow issues, caregiver acceptability, staff implementation burden, tolerability, and completeness of study data.

Exploratory clinical variables will include routine ESC assessments, feeding support including nasogastric feeding where required, pharmacologic treatment for NOWS, cumulative medication exposure where available, treatment duration, medical readiness for discharge, and hospital length of stay.

Because this is a small feasibility study without a control group, analyses will be primarily descriptive and estimation-based. The study is not powered for efficacy testing, and no formal between-group hypothesis testing or multivariable modeling is planned. Findings will be used to refine the intervention and procedures and to inform the design of a future randomized efficacy trial.

02

Conditions studied

  • Neonatal Opioid Withdrawal Syndrome
  • Prenatal Opioid Exposure
  • Opioid Withdrawal
  • Neonatal Abstinence Syndrome

Keywords

  • Neonatal opioid withdrawal syndrome
  • NOWS
  • Neonatal abstinence syndrome
  • NAS
  • Eat, Sleep, Console
  • ESC
  • Parent/caregiver voice
  • Recorded voice
  • Non-pharmacologic intervention
  • Prenatal opioid exposure
  • Neonatal intensive care unit
  • NICU
  • Feasibility study
03

In context

Neonatal Abstinence Syndrome

68 studies on the registry are indexed under Neonatal Abstinence Syndrome; 6 are open to participants now.

This study's planned enrollment of 20 is below the median of 48 across 52 interventional studies indexed under Neonatal Abstinence Syndrome.

Browse Neonatal Abstinence Syndrome studies →

Lead sponsor

University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonate receiving care at HSC Women's Hospital or St. Boniface Hospital.
  • Prenatal opioid exposure with clinical neonatal opioid withdrawal syndrome (NOWS).
  • Managed using an Eat, Sleep, Console (ESC)-based approach.
  • Requires NICU care or escalation of care for ongoing management of NOWS.
  • Parent/legal guardian is able to provide for study participation.
  • A parent/caregiver is willing and able to provide a usable voice recording for the intervention. The recording may be provided in the caregiver's preferred or native language.
  • Opioid-associated polysubstance exposure is permitted provided opioid exposure is present and the infant is being managed for NOWS.

Exclusion criteria

Exclusion Criteria:

  • NICU admission primarily for prematurity or another medical condition unrelated to NOWS.

Requirement for nasal continuous positive airway pressure (NCPAP/CPAP) or other respiratory support for an independent respiratory condition at the time the intervention would be delivered.

  • Withdrawal symptoms attributable solely to non-opioid substance exposure without prenatal opioid exposure.
  • Clinical condition in which the treating team considers recorded voice playback inappropriate or unsafe.
  • Any clinical or operational circumstance that prevents safe delivery of the intervention according to protocol.
  • Parent/legal guardian consent cannot be obtained.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Recorded Parent/Caregiver Voice Plus Standard ESC Care

    All enrolled infants will receive standard Eat, Sleep, Console (ESC)-based care together with the recorded parent/caregiver voice intervention. A parent/caregiver will provide a voice recording in their preferred or native language. Playback will be integrated into clinically appropriate feeding and settling periods, generally during the latter part of feeding and/or immediately after feeding while the infant is settling or attempting to sleep. Direct parent/caregiver interaction and all clinically indicated care will take priority over recorded playback.

    Behavioral: Recorded Parent/Caregiver Voice Playback

Interventions

  • BehavioralRecorded Parent/Caregiver Voice Playback

    A participating parent/caregiver will provide a recorded voice sample using natural speech in their preferred or native language. The recording may include talking, reading, singing, storytelling, or comforting words. The recording will be played to the infant during protocol-defined, clinically appropriate feeding and settling periods, generally during the latter part of feeding and/or immediately after feeding while the infant is attempting to settle or sleep. Playback sessions will generally last approximately 20 minutes unless stopped earlier. Sound will be targeted at approximately 45-50 dB(A) at the infant position and will not exceed the protocol-defined maximum of 55 dB(A). Playback will be withheld, paused, or discontinued for infant distress or clinical instability, clinical procedures or care needs, direct parent/caregiver interaction, unsuitable environmental conditions, parent/caregiver request, treating-team concern, or inability to maintain protocol-defined sound paramet

06

What researchers measure

Primary outcomes

  1. Proportion of Enrolled Infants With a Usable Parent/Caregiver Voice Recording Obtained

    Number of enrolled infants for whom a usable parent/caregiver voice recording is successfully obtained, divided by the total number of enrolled infants, expressed as a percentage. A usable recording is one that can be used for protocol-defined playback.

    Time frame: From enrollment until the first usable parent/caregiver voice recording is obtained, assessed up to 1 day after enrollment

  2. Proportion of Prescribed Voice Playback Sessions Successfully Delivered

    Number of protocol-prescribed recorded parent/caregiver voice playback sessions successfully delivered, divided by the total number of prescribed playback sessions, expressed as a percentage. Sessions that are missed, withheld, interrupted, or discontinued will be documented together with the reason.

    Time frame: From the first planned playback session through completion of the intervention period, assessed up to 28 days after enrollment

Secondary outcomes

  1. Proportion of Eligible Infants Enrolled

    Number of eligible infants whose parent/legal guardian provides consent and who are enrolled, divided by the total number of eligible infants approached for participation, expressed as a percentage.

    Time frame: Throughout the recruitment period, approximately 12 months

  2. Time From Enrollment to Availability of a Usable Parent/Caregiver Voice Recording

    Elapsed time between study enrollment and availability of the first usable parent/caregiver voice recording for intervention delivery.

    Time frame: From enrollment until the first usable parent/caregiver voice recording is available, assessed up to 1 day after enrollment

  3. Occurrence of Infant Intolerance During Recorded Voice Playback

    Number and proportion of infants with a documented behavioral or physiological concern temporally associated with playback that results in pausing, withholding, or discontinuing a session.

    Time frame: From the first playback session through completion of the intervention period, assessed up to 28 days after enrollment

  4. Parent/Caregiver Acceptability of the Recorded Voice Intervention

    Acceptability of the intervention as assessed using the study-specific parent/caregiver acceptability questionnaire, including perceived ease of providing the recording and acceptability of using recorded voice as part of the infant's supportive care. Results will be summarized descriptively.

    Time frame: At completion of the intervention period or before hospital discharge, whichever occurs first, assessed up to 28 days after enrollment

  5. Frequency of Protocol Deviations and Intervention Delivery Problems

    Number and type of protocol deviations, equipment or sound-delivery issues, workflow barriers, and other implementation problems occurring during study participation.

    Time frame: From initiation through completion of the intervention period, assessed up to 28 days after enrollment

Other outcomes

  1. Pharmacologic Treatment for NOWS

    Occurrence and amount of pharmacologic treatment for neonatal opioid withdrawal syndrome, including PRN and scheduled/maintenance opioid therapy and adjunct medications where applicable.

    Time frame: From enrollment through hospital discharge, assessed over an anticipated period of up to 28 days

  2. Hospital Length of Stay

    Number of days from hospital admission to hospital discharge.

    Time frame: From hospital admission until hospital discharge, assessed over an anticipated period of up to 28 days

07

Study locations

2 sites
08

References and documents

Publications

  • Li Y, Zhang J, Yang C, Xia B. Effects of maternal sound stimulation on preterm infants: A systematic review and meta-analysis. Int J Nurs Pract. 2023 Apr;29(2):e13039. doi: 10.1111/ijn.13039. Epub 2022 Feb 21. PubMed 35187754 ↗
  • Provenzi L, Broso S, Montirosso R. Do mothers sound good? A systematic review of the effects of maternal voice exposure on preterm infants' development. Neurosci Biobehav Rev. 2018 May;88:42-50. doi: 10.1016/j.neubiorev.2018.03.009. Epub 2018 Mar 10. PubMed 29535067 ↗
  • Filippa M, Panza C, Ferrari F, Frassoldati R, Kuhn P, Balduzzi S, D'Amico R. Systematic review of maternal voice interventions demonstrates increased stability in preterm infants. Acta Paediatr. 2017 Aug;106(8):1220-1229. doi: 10.1111/apa.13832. Epub 2017 Apr 19. PubMed 28378337 ↗
  • Young LW, Ounpraseuth ST, Merhar SL, Hu Z, Simon AE, Bremer AA, Lee JY, Das A, Crawford MM, Greenberg RG, Smith PB, Poindexter BB, Higgins RD, Walsh MC, Rice W, Paul DA, Maxwell JR, Telang S, Fung CM, Wright T, Reynolds AM, Hahn DW, Ross J, McAllister JM, Crowley M, Shaikh SK, Puopolo KM, Christ L, Brown J, Riccio J, Wong Ramsey K, Akshatha, Braswell EF, Tucker L, McAlmon KR, Dummula K, Weiner J, White JR, Howell MP, Newman S, Snowden JN, Devlin LA; ACT NOW Collaborative. Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal. N Engl J Med. 2023 Jun 22;388(25):2326-2337. doi: 10.1056/NEJMoa2214470. Epub 2023 Apr 30. PubMed 37125831 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 18 interventional studies with no phase under Neonatal Abstinence Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 7, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • St. Boniface Hospital · Winnipeg, CanadaContact added F•••@hsc.mb.ca · •••4992
  • HSC Winnipeg Women's Hospital · Winnipeg, CanadaContact added j•••@hsc.mb.ca · •••1991
Oct 8, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 8, 2026
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • St. Boniface Hospital · Winnipeg, CanadaContact added F•••@hsc.mb.ca · •••4992
    • HSC Winnipeg Women's Hospital · Winnipeg, CanadaContact added j•••@hsc.mb.ca · •••1991
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864493
Responsible party
Mohamed Habib (Neonatal-Perinatal Medicine Fellow / Principal Investigator, University of Manitoba) — Principal investigator
First posted
Oct 7, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Mohamed Habib, MD
Contact
mhabib3@hsc.mb.ca
431-998-8002
Michael Narvey, MD
Contact
mnarvey@hsc.mb.ca
204-899-6845
Mohamed Habib, MD
principal investigator · University of Manitoba
Michael Narvey, MD
study director · University of Manitoba

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion